Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

Evofem Biosciences, Inc.

CIK 1618835 EVFM·Pharmaceutical Preparations · All EDGAR filings ↗

Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

Evofem Biosciences, Inc. no longer reports substantial doubt about going concern

Substantial doubt about ability to continue as a going concern → No substantial-doubt conclusion identified

There can be no assurance that the Company will be successful in doing so, and failure to satisfy or restructure these obligations could result in additional defaults, enforcement actions and other material adverse consequences to the Company’s business, financial condition and ability to continue as a going concern. Management’s plans to meet its cash flow needs in the next 12 months includes generating recurring product revenue from PHEXX and SOLOSEC, earning milestone payments triggered by the achievement of certain regulatory milestones under the License and Supply Agreement with Pharma 1…
Evidence
Blank check
No
Comparable
Yes
Current state
none
Current state label
No substantial-doubt conclusion identified
Direction
eased
Located in
going-concern note
Prior filed
2026-08-14
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Going concern Filing comparison

Evofem Biosciences, Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, negative cash flows from operations since inception, and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-03-28
Prior form
10-K/A
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗